Related Experiment Video
Updated: May 26, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Mutagenicity of ipriflavone in vivo and in vitro
Luciano Belcavello1, Jean Carlos Vencioneck Dutra, Josivany Valério de Freitas
1Departamento de Ciências Biológicas, Universidade Federal do Espírito Santo, Vitória, ES, Brazil. belcavello@gmail.com
Abstract:
Ipriflavone (7-isopropoxy-isoflavone) is a semisynthetic isoflavone derivative from daidzein and prescribed to prevent and treat osteoporosis in postmenopausal women. In the present study, ipriflavone was investigated with regard to their cytotoxic and mutagenic effects using the micronucleus assay (MN) in vivo on cells of bone marrow and peripheral blood of Swiss albino mice and the micronucleus test with the cytokinesis-blocked micronucleus assay (CBMN assay) on human peripheral blood lymphocytes. The studies were performed in mice with three dosages of the drug, 1.71, 8.57 and 42.85 mg/kg bw in single oral exposure, and for two dosages, 5 and 10 μg/mL in the CBMN assay. Ipriflavone, in the dosages tested, did not differ from controls neither in the induction of MN nor induced cytotoxicity to cells in the in vivo test. However, in the CBMN assay, the concentration of 10 μg/mL induced a statistically significant increase in MN formation and decreased cell proliferation, demonstrating to be mutagenic and cytotoxic at this concentration.
Related Concept Videos
Mutagenicity and Carcinogenicity
In vitro Mutagenesis
In-vitro Mutagenesis
Drug Product Performance: In Vitro–In Vivo Correlation
In Vitro Drug Release Testing: Overview, Development and Validation
Teratogenicity

